Efficacy and safety of omalizumab in patients with moderate-to-severe asthma: An analytic comparison of data from randomized controlled trials between Chinese and Caucasians

Jing Li; Jing Yang; Lingfei Kong; Yijiang Huang; Ping Chen; Xixin Yan; Xiaoxia Liu; Xiangdong Zhou; Jinming Liu; Xiaoli Zhu; Michael Humphries; Linda Wang; Abhijit Pethe; Xinting Wang; Ioannis Kottakis; Robert Fogel; Nanshan Zhong

doi:10.12932/ap-260819-0630

Efficacy and safety of omalizumab in patients with moderate-to-severe asthma: An analytic comparison of data from randomized controlled trials between Chinese and Caucasians

Jing Li, Jing Yang, Lingfei Kong, Yijiang Huang, Ping Chen, Xixin Yan, Xiaoxia Liu, Xiangdong Zhou, Jinming Liu, Xiaoli Zhu, Michael Humphries, Linda Wang, Abhijit Pethe, Xinting Wang, Ioannis Kottakis, Robert Fogel, Nanshan Zhong

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	223-231
Number of pages	9
Journal	Asian Pacific Journal of Allergy and Immunology
Volume	40
Issue number	3
DOIs	https://doi.org/10.12932/ap-260819-0630
State	Published - Sep 2022
Externally published	Yes

ASJC Scopus Subject Areas

General Medicine

Keywords

Asthma
Caucasian
Chinese
comparative analysis
omalizumab

Access to Document

10.12932/ap-260819-0630

OpenUrl availability

Full text

Cite this

Li, J., Yang, J., Kong, L., Huang, Y., Chen, P., Yan, X., Liu, X., Zhou, X., Liu, J., Zhu, X., Humphries, M., Wang, L., Pethe, A., Wang, X., Kottakis, I., Fogel, R., & Zhong, N. (2022). Efficacy and safety of omalizumab in patients with moderate-to-severe asthma: An analytic comparison of data from randomized controlled trials between Chinese and Caucasians. Asian Pacific Journal of Allergy and Immunology, 40(3), 223-231. https://doi.org/10.12932/ap-260819-0630

Efficacy and safety of omalizumab in patients with moderate-to-severe asthma: An analytic comparison of data from randomized controlled trials between Chinese and Caucasians. / Li, Jing; Yang, Jing; Kong, Lingfei et al.
In: Asian Pacific Journal of Allergy and Immunology, Vol. 40, No. 3, 09.2022, p. 223-231.

Research output: Contribution to journal › Article › peer-review

Li, J, Yang, J, Kong, L, Huang, Y, Chen, P, Yan, X, Liu, X, Zhou, X, Liu, J, Zhu, X, Humphries, M, Wang, L, Pethe, A, Wang, X, Kottakis, I, Fogel, R & Zhong, N 2022, 'Efficacy and safety of omalizumab in patients with moderate-to-severe asthma: An analytic comparison of data from randomized controlled trials between Chinese and Caucasians', Asian Pacific Journal of Allergy and Immunology, vol. 40, no. 3, pp. 223-231. https://doi.org/10.12932/ap-260819-0630

@article{cf5e5f827ca0493384a5a66091fae8bd,

title = "Efficacy and safety of omalizumab in patients with moderate-to-severe asthma: An analytic comparison of data from randomized controlled trials between Chinese and Caucasians",

keywords = "Asthma, Caucasian, Chinese, comparative analysis, omalizumab",

author = "Jing Li and Jing Yang and Lingfei Kong and Yijiang Huang and Ping Chen and Xixin Yan and Xiaoxia Liu and Xiangdong Zhou and Jinming Liu and Xiaoli Zhu and Michael Humphries and Linda Wang and Abhijit Pethe and Xinting Wang and Ioannis Kottakis and Robert Fogel and Nanshan Zhong",

year = "2022",

month = sep,

doi = "10.12932/ap-260819-0630",

language = "English",

volume = "40",

pages = "223--231",

journal = "Asian Pacific Journal of Allergy and Immunology",

issn = "0125-877X",

number = "3",

}

TY - JOUR

T1 - Efficacy and safety of omalizumab in patients with moderate-to-severe asthma

T2 - An analytic comparison of data from randomized controlled trials between Chinese and Caucasians

AU - Li, Jing

AU - Yang, Jing

AU - Kong, Lingfei

AU - Huang, Yijiang

AU - Chen, Ping

AU - Yan, Xixin

AU - Liu, Xiaoxia

AU - Zhou, Xiangdong

AU - Liu, Jinming

AU - Zhu, Xiaoli

AU - Humphries, Michael

AU - Wang, Linda

AU - Pethe, Abhijit

AU - Wang, Xinting

AU - Kottakis, Ioannis

AU - Fogel, Robert

AU - Zhong, Nanshan

PY - 2022/9

Y1 - 2022/9

KW - Asthma

KW - Caucasian

KW - Chinese

KW - comparative analysis

KW - omalizumab

UR - http://www.scopus.com/inward/record.url?scp=85136341355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85136341355&partnerID=8YFLogxK

U2 - 10.12932/ap-260819-0630

DO - 10.12932/ap-260819-0630

M3 - Article

C2 - 32247304

AN - SCOPUS:85136341355

SN - 0125-877X

VL - 40

SP - 223

EP - 231

JO - Asian Pacific Journal of Allergy and Immunology

JF - Asian Pacific Journal of Allergy and Immunology

IS - 3

ER -

Efficacy and safety of omalizumab in patients with moderate-to-severe asthma: An analytic comparison of data from randomized controlled trials between Chinese and Caucasians

ASJC Scopus Subject Areas

Keywords

Access to Document

OpenUrl availability

Other files and links

Cite this